44 / 63
Sarcopenia y toxicidad de la Qt en pacientes
oncológicos
“The emerging role of sarcopenia in
predicting lean mass may provide
the tool needed to
more accurately
dose patients
and prevent dose-
limiting toxicities.”
Hopkins JJ. Expert Rev Clin
Pharmacol 2017;10(9):947-56
“Future clinical trials investigating
dose reductions in patients
with sarcopenia and dose-
escalating
studies based on pre-
treatment body composition
assessment have the potential to
alter cancer treatment
paradigms”.
Prado CM et al. Anticancer
Agents Med Chem
2013;13(8):1197-203